Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2858747 | 0.94 | BRD4 (0.38) | KDM4ECA2CHKAHRH1BRD4 | |
| SCHEMBL10525669 | 0.84 | BRD4 (0.39) | BRD4BRD2ALDH1A1MAPTHSD17B10 | |
| SCHEMBL1440029 | 0.82 | ALDH1A1 (0.37) | KDM4ESMN1; SMN2BRD4BRD2GAA | |
| SCHEMBL27755656 | 0.82 | BRD4 (0.35) | BRD4BRD2 | |
| SCHEMBL442676 | 0.80 | BRD4 (0.44) | BRD4BRD2ALDH1A1 | |
| SCHEMBL2997559 | 0.78 | BRD4 (0.42) | KDM4EBRD4BRD2GAAPOLB | |
| SCHEMBL2529557 | 0.78 | HTR2C (0.34) | KDM4EBRD4BRD2GAAPOLB | |
| SCHEMBL1440028 | 0.77 | BRD4 (0.43) | BRD4BRD2ALDH1A1MAPTHSD17B10 | |
| SCHEMBL4766947 | 0.75 | ALDH1A1 (0.34) | KDM4ESMN1; SMN2BRD4BRD2GAA | |
| SCHEMBL28478099 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2208726-B1 | Cyclic amide derivatives, and their production and use as antithrombotic agents | TAKEDA PHARMACEUTICAL (JP) | 2014-08-20 | — | — | EP | disclosed |
| US-8697865-B2 | Cyclic amide derivative, and its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-15 | — | — | US | disclosed |
| EP-1748985-B1 | CYCLIC AMIDE DERIVATIVES, AND THEIR PRODUCTION AND USE AS ANTITHROMBOTIC AGENTS | TAKEDA PHARMACEUTICAL (JP) | 2011-06-22 | — | — | EP | disclosed |
| EP-2208726-A1 | Cyclic amide derivatives, and their production and use as antithrombotic agents | Takeda Pharmaceutical Company Limited (JP) | 2010-07-21 | — | — | EP | disclosed |
| US-7745623-B2 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20100160629-A1 | CYCLIC AMIDE DERIVATIVE, AND ITS PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| CN-101326178-A | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORP (US) | 2008-12-17 | — | — | CN | disclosed |
| US-20080255362-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255352-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20070244118-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-10-18 | — | — | US | disclosed |
| EP-1790636-A1 | PIPERIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1748985-A1 | CYCLIC AMIDE DERIVATIVES, AND THEIR PRODUCTION AND USE AS ANTITHROMBOTIC AGENTS | Takeda Pharmaceutical Company Limited (JP) | 2007-02-07 | — | — | EP | disclosed |
| US-20060142337-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-29 | — | — | US | disclosed |
| WO-2005113504-A1 | CYCLIC AMIDE DERIVATIVES, AND THEIR PRODUCTION AND USE AS ANTITHROMBOTIC AGENTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255352-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, F2 | KDM4E 4074/4885CA2 897/4885CHKA 3028/4885 |
| US-20100160629-A1 | CYCLIC AMIDE DERIVATIVE, AND ITS PRODUCTION AND USE | CNR1, CNR2, ARG1 | KDM4E 2683/4885CA2 1020/4885CHKA 1845/4885 |
| US-20060142337-A1 | Piperidine derivative and use thereof | AR, AHR, ARNT | KDM4E 1123/4885CA2 2960/4885CHKA 4717/4885 |
| US-20070244118-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, CNR2 | KDM4E 4199/4885CA2 996/4885CHKA 3210/4885 |
| US-20080255362-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, F2 | KDM4E 4074/4885CA2 897/4885CHKA 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.